Hasil Pencarian - Dorothée Semiond

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

    Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients oleh Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara, Hirotaka Kazama, Jean‐Baptiste Fau, Dorothée Semiond, Christine Veyrat‐Follet

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

    Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients oleh Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

    PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma oleh Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai, Claire Brillac, Jean‐Baptiste Fau, Christine Veyrat‐Follet, Marie‐Laure Risse, Helgi van deVelde, Dorothée Semiond, Laurent Nguyen

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

    Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom... oleh Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

    A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma oleh Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothee Semiond, Disa Yu, Paul Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

    A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab oleh Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder, Djordje Atanackovic, Nashat Gabrail, Thomas G. Martin, Aurore Perrot, Samira Bensfia, Qilong Weng, Claire Brillac, Dorothée Semiond, Sandrine Macé, Kathryn P. Corzo, Xavier Leleu

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: